Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the Phase 1 portion of the study, which will be conducted in the US only, is to determine the maximum tolerated dose (MTD) of ABT-751 when administered daily for 14/21 days, in combination with standard pemetrexed (500 mg/m2 every 21 days).The primary objective of the Phase 2 portion of the study (estimated to begin enrollment in Sep-Nov 2006) is to assess the impact on progression-free survival of the combination of ABT-751 + pemetrexed compared to pemetrexed alone in subjects with NSCLC who have received at least one prior chemotherapy regimen.
Inclusion criteria
- Advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens